Form 4: AbCellera Biologics CEO Carl Hansen Reports Stock Transactions
SEC Form 4 Filing
Carl Hansen, CEO of AbCellera Biologics, reports the acquisition and disposal of common shares and the exercise of share options.
Summary
- On September 20, 2024, Carl Hansen, CEO of AbCellera Biologics, engaged in transactions involving the company's stock.
- Hansen acquired 56,125 common shares at a price of $2.70.
- He also disposed of 841,875 common shares.
- Following these transactions, Hansen directly owns 56,086,009 common shares indirectly through Thermopylae Holdings Ltd., an entity wholly owned by him.
- Hansen also exercised a share option for 56,125 shares at a price of $2.70.
- Following the transaction, Hansen directly owns 8,316,348 share options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transactions may influence investor perception of the company's stock.
Key Dates
| Date | Description |
|---|---|
| 11/18/2021 | First tranche of share options vested. |
| 09/20/2024 | Date of stock acquisition, disposal, and option exercise. |
| 09/24/2024 | Date of signature by attorney-in-fact. |
| 11/27/2030 | Expiration date of share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.